๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› New Delhi
Clinical trial register · India

Clinical Trials in New Delhi

Every study on the ClinicalTrials.gov registry that lists a site in India and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 1123 matching records held by the registry are in this view. Synced 21 Sep 2026, 03:16 UTC
1123
Studies in scope
all four open statuses
610
Recruiting now
open to new participants
222
Lead sponsors
across recruiting studies
Top sites
New Delhi 22 Hyderabad 15 Ahmedabad 12 Pune 12 Bangalore 11
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Institute of Liver and Biliary Sciences, India46 AstraZeneca38 Novartis Pharmaceuticals22 Bristol-Myers Squibb18 Eli Lilly and Company17 Clear sponsor filter
Site location
New Delhi22 Hyderabad15 Ahmedabad12 Pune12 Bangalore11
All 45 locations
Target enrolment
to
22 of 1123 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Indian sites
Start
Recruiting
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
NCT07225504Secondary Progressive Multiple Sclerosis (SPMS)
Novartis Pharmaceuticals
Phase 3
1,275
Gurugram, Mangalore, Kochi, New Delhi, Chandigarh, Vellore, Hyderabad
2025-11-11
Recruiting
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
NCT06744920Generalized Myasthenia Gravis
Novartis Pharmaceuticals
Phase 3
180
Gurugram, Mangalore, Nashik, New Delhi, Ludhiana, Vellore, Hyderabad, Lucknow
2025-02-07
Recruiting
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
NCT06470048Diffuse Cutaneous Systemic Sclerosis
Novartis Pharmaceuticals
Phase 2
200
Kochi, Mumbai, New Delhi, Jaipur
2024-10-09
Recruiting
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
NCT06133972Systemic Lupus Erythematosus
Novartis Pharmaceuticals
Phase 3
550
Ahmedabad, Kozhikode, Kolhฤpur, Nagpur, Nashik, Pune, New Delhi
2024-05-21
Recruiting
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
NCT05827081Early Breast Cancer
Novartis Pharmaceuticals
Phase 3
1,400
Hyderabad, Bangalore, Mumbai, Pune, New Delhi, Bhubaneswar, Chennai, Kolkata
2024-02-28
Active, closed
Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.
NCT06042478Chronic Spontaneous Urticaria
Novartis Pharmaceuticals
Phase 3
470
Ahmedabad, Bangalore, Belagavi, Mysore, Nagpur, Nashik, New Delhi, Bikaner
2023-11-15
Active, closed
A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
NCT05985915Sjogrens Syndrome
Novartis Pharmaceuticals
Phase 3
612
Ahmedabad, New Delhi
2023-10-27
Recruiting
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
NCT05755386IC-MPGN
Novartis Pharmaceuticals
Phase 3
106
Bangalore, Nagpur, Pune, New Delhi, Hyderabad
2023-10-02
Active, closed
Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)
NCT05624749Systemic Lupus Erythematosus
Novartis Pharmaceuticals
Phase 3
288
Ahmedabad, Kozhikode, Kolhฤpur, Nagpur, Nashik, Pune, New Delhi, Dehradun
2023-04-21
Active, closed
A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia
NCT05648968Warm Autoimmune Hemolytic Anemia (wAIHA)
Novartis Pharmaceuticals
Phase 3
90
New Delhi, Madurai, Hyderabad, Lucknow
2022-12-30
Active, closed
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (โ‰ฅ18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
NCT05456191Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
Novartis Pharmaceuticals
Phase 3
568
Ahmedabad, New Delhi, Chennai, Varanasi, Rishikesh
2022-11-21
Recruiting
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
NCT05268289Lupus Nephritis
Novartis Pharmaceuticals
Phase 2
240
Ahmedabad, Kozhikode, New Delhi, Vellore, Hyderabad, Lucknow, Puducherry
2022-08-10
Active, closed
Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome
NCT05349214Sjogren Syndrome
Novartis Pharmaceuticals
Phase 3
506
Ahmedabad, Bangalore, Pune, New Delhi
2022-08-04
Active, closed
Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events
NCT05360446Coronary Artery Disease
Novartis Pharmaceuticals
Phase 3
609
Bangalore, New Delhi, Chennai, Coimbatore, Lucknow, Dehradun
2022-07-08
Active, closed
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)
NCT05147220Relapsing Multiple Sclerosis
Novartis Pharmaceuticals
Phase 3
1,000
Mangalore, Mumbai, Nashik, New Delhi, Chandigarh, Ludhiana, Lucknow, Dehradun
2021-12-16
Active, closed
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)
NCT05156281Relapsing Multiple Sclerosis
Novartis Pharmaceuticals
Phase 3
1,007
Kochi, Pune, New Delhi, Amritsar, Hyderabad, Lucknow, Kolkata
2021-12-13
Active, closed
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer
NCT04940052Differentiated Thyroid Cancer (DTC)
Novartis Pharmaceuticals
Phase 3
153
Hisar, New Delhi, Chennai
2021-11-15
Active, closed
Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis
NCT04926818Multiple Sclerosis (MS)
Novartis Pharmaceuticals
Phase 3
129
New Delhi, Lucknow, Kolkata
2021-10-05
Active, closed
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
NCT04557462Primary IgA Nephropathy
Novartis Pharmaceuticals
Phase 3
448
Bangalore, New Delhi, Hyderabad
2021-09-20
Recruiting
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
NCT04817618C3G
Novartis Pharmaceuticals
Phase 3
98
New Delhi, Hyderabad, Lucknow, Dehradun
2021-07-28
Recruiting
Secukinumab Open Label Roll-over Extension Protocol
NCT04638647Autoimmunity, Inflammation
Novartis Pharmaceuticals
Phase 4
1,000
Surat, Bangalore, Mumbai, Nashik, New Delhi, Hyderabad
2020-12-22
Active, closed
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
NCT03650114Relapsing Multiple Sclerosis
Novartis Pharmaceuticals
Phase 3
1,882
Mangalore, Kochi, Mumbai, Pune, New Delhi, Chandigarh, Hyderabad, Howrah
2018-12-28
Rows per page Showing 1–22 of 22
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Indian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 21 September 2026. https://priyalifescience.com/clinical-trials-india/city/new-delhi

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.